Angiotech Pharmaceuticals

ANP-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about ANP-T

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
June 22, 2005
Comes into the health care theme that he thinks will be dominate into the next 10 years. Not his favourite way to participate.
Show full opinionHide full opinion
Comes into the health care theme that he thinks will be dominate into the next 10 years. Not his favourite way to participate.
DON'T BUY
DON'T BUY
March 29, 2005
Boston Scientific (BSX-N) had the majority share in the business, they are a supplier, so why is it weak. Boston is just as weak. The problem with the pharma sector is investors never look at what it is today but what is the marginal change tomorrow, such as competition with a better product.
Show full opinionHide full opinion
Boston Scientific (BSX-N) had the majority share in the business, they are a supplier, so why is it weak. Boston is just as weak. The problem with the pharma sector is investors never look at what it is today but what is the marginal change tomorrow, such as competition with a better product.
VAGUE
VAGUE
March 11, 2005
Technology is superior then Boston Scientific, and Boston markets for them. (for their main product). Would rather buy Boston, because it is more diversified, and slightly cheaper.
Show full opinionHide full opinion
Technology is superior then Boston Scientific, and Boston markets for them. (for their main product). Would rather buy Boston, because it is more diversified, and slightly cheaper.
BUY
BUY
February 14, 2005
Longer term, they're going to have to start filling their pipeline more. Coated stents have been a great success. Distributor, Boston Scientific, have about 70% of the market so far which will generate great cash over the next couple of years. Management is good and should be able to redeploy cash to build up by acquisitions, etc.
Show full opinionHide full opinion
Longer term, they're going to have to start filling their pipeline more. Coated stents have been a great success. Distributor, Boston Scientific, have about 70% of the market so far which will generate great cash over the next couple of years. Management is good and should be able to redeploy cash to build up by acquisitions, etc.
VAGUE
VAGUE
February 7, 2005
The coating on the stents seems to be a bit better than the ones from Johnson & Johnson.
Show full opinionHide full opinion
The coating on the stents seems to be a bit better than the ones from Johnson & Johnson.
DON'T BUY
Fully valued.
WAIT
WAIT
February 7, 2005
His technical screening looks for stocks that are forming base patterns. Starting to see that now and starting to get a little bit attractive. Hasn't done anything positive in terms of upside volume, surges or money flow. Once you see that, the story gets really exciting.
Show full opinionHide full opinion
His technical screening looks for stocks that are forming base patterns. Starting to see that now and starting to get a little bit attractive. Hasn't done anything positive in terms of upside volume, surges or money flow. Once you see that, the story gets really exciting.
BUY
BUY
December 16, 2004
As an emerging technology, the stock got a very high multiple, but once it gets up there, how do you keep that high multiple? Very difficult unless you continue to have new products and excitement. A solid company with a solid product, but doesn't think it will ever get the multiple that it had before. Probably an OK buy today.
Show full opinionHide full opinion
As an emerging technology, the stock got a very high multiple, but once it gets up there, how do you keep that high multiple? Very difficult unless you continue to have new products and excitement. A solid company with a solid product, but doesn't think it will ever get the multiple that it had before. Probably an OK buy today.
DON'T BUY
DON'T BUY
November 16, 2004
Had a major sell off and is probably in some what of a support zone. Still below its 200 day moving average.
Show full opinionHide full opinion
Had a major sell off and is probably in some what of a support zone. Still below its 200 day moving average.
PAST TOP PICK
PAST TOP PICK
November 11, 2004
(A Top Pick June 23/04. Down 15%.) Had a recall of their stent 2 days later and they dropped market share to 55%, but are now back to 70%. Still buying.
Show full opinionHide full opinion
(A Top Pick June 23/04. Down 15%.) Had a recall of their stent 2 days later and they dropped market share to 55%, but are now back to 70%. Still buying.
BUY
BUY
November 5, 2004
A good probability that the stock will move higher. Everything is lining up for them to get a higher royalty from Boston Scientific.
Show full opinionHide full opinion
A good probability that the stock will move higher. Everything is lining up for them to get a higher royalty from Boston Scientific.
PAST TOP PICK
PAST TOP PICK
October 21, 2004
(A Top Pick Aug 17/04. Up 11%.) Their distributor, Boston Scientific, have announced very good results. Market share is back to where it was before the stent recall. Looking to expand their technology in stents.
Show full opinionHide full opinion
(A Top Pick Aug 17/04. Up 11%.) Their distributor, Boston Scientific, have announced very good results. Market share is back to where it was before the stent recall. Looking to expand their technology in stents.
HOLD
HOLD
October 19, 2004
Bullish on this company. Revenue stream from their coated stents is looking quite strong.
Show full opinionHide full opinion
Bullish on this company. Revenue stream from their coated stents is looking quite strong.
DON'T BUY
DON'T BUY
September 30, 2004
A very volatile stock. A one product stock.
Show full opinionHide full opinion
A very volatile stock. A one product stock.
BUY
BUY
September 29, 2004
Looking at it. Likes the stock. Long term buy.
Show full opinionHide full opinion
Looking at it. Likes the stock. Long term buy.
Showing 46 to 60 of 140 entries